More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.31B
EPS
-0.29
P/E ratio
--
Price to sales
5.08
Dividend yield
--
Beta
2.65097
Previous close
$8.06
Today's open
$8.05
Day's range
$7.88 - $8.14
52 week range
$6.20 - $13.39
show more
CEO
JOHN C. JACOBS
Employees
749
Headquarters
Gaithersburg, MD
Exchange
Nasdaq Global Select
Shares outstanding
165009009
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial
Novavax NASDAQ: NVAX is looking to expand partnerships around its vaccine technology while advancing a potential C. difficile vaccine and supporting partner Sanofi's development of a combination COVID-19 and flu shot, executives said at the Jefferies 2026 Global Healthcare Conference in London.
MarketBeat • Nov 17, 2026

Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md., Nov. 11, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conference: Jefferies London Healthcare Conference, London, United KingdomFireside chat on Tuesday, November 17, 2026, at 5:00 p.m.
PRNewsWire • Nov 11, 2026

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks Investment Research • Nov 10, 2026

Novavax Q3 Earnings Call Highlights
Novavax NASDAQ: NVAX raised its 2026 revenue framework after partner Sanofi began a late-stage trial of a combination influenza and COVID-19 vaccine in Europe, triggering a $125 million milestone payment for the vaccine technology company.
MarketBeat • Nov 6, 2026

NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline
Novavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.
Zacks Investment Research • Nov 6, 2026

Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
Reports total revenue of $68 million for the third quarter of 2026 Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and SG&A expense guidance by $5 million at mid-point In October, Novavax earned a $125 million milestone upon Sanofi's launch of Phase 3 influenza-COVID-19 combination vaccine trial in Europe Sanofi confirms their intent to initiate a U.S. Phase 3 influenza-COVID-19 combination vaccine trial in 2027 to support U.S. approval Differentiated C. difficile vaccine program anticipated to advance into the clinic as early as 2027 Multiple Novavax and partner-led experiments with Matrix-M ® currently underway in a wide array of infectious disease targets and oncology models Company to host conference call today at 8:30 a.m.
PRNewsWire • Nov 5, 2026

Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
Novavax (NVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.62 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S. financial markets on Thursday, November 5, 2026.
PRNewsWire • Oct 29, 2026

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease 1 The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine Significant potential value remains in Sanofi partnership via additional future opportunities for milestones and royalties GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™.
PRNewsWire • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Novavax Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.